Cushing’s Disease in an Obese Patient Accompanied by Recurrent Urinary Tract Infection and Nephrolithiasis

Seonghyup Hyun; Jae Woong Kim; Moon Ki Hong; Mi Yi Kim; Seung Eun Lee; Seok Hong Lee; Jaetaek Kim; Jihyun Ahn

Article

Korean J Obes 2011; 20(4): 219-221

Published online December 1, 2011

Cushing’s Disease in an Obese Patient Accompanied by Recurrent Urinary Tract Infection and Nephrolithiasis

Seonghyup Hyun, Jae Woong Kim, Moon Ki Hong, Mi Yi Kim,Seung Eun Lee, Seok Hong Lee, Jaetaek Kim, Jihyun Ahn^*

Author Affiliations

Department of Internal Medicine, College of Medicine, Chung-Ang University

Abstract

Go to

Abstract
Figure
References

Cushing’s disease can cause obesity, diabetes and hypertension. Nephrolithiasis is prevalent in obese population. A variety of factors influence the formation of nephrolithiasis such as gender, diet, and urinary excretion of calcium, oxalate, and uric acid. We report a case of Cushing’s disease in an obese diabetic patient accompanied by recurrent urinary tract infection and nephrolithiasis. After the removal of pituitary tumor, diabetes and urinary tract infection were completely remitted.

Keywords: Cushing disease, Obesity, Nephrolithiasis

Figures

Go to

Abstract
Figure
References

Fig. 1. Abdominal CT scan shows a large staghorn stone in right kidney and perinephric fat infiltration which is compatible for pyelonephritis.

Fig. 2. Sella MR shows 9 × 6.5 mm sized microadenoma in right wing of pituitary gland without cavernous sinus involvement.

References

Go to

Abstract
Figure
References

Faggiano A, Pivonello R, Melis D, Filippella M, Di Somma C, Petretta M, et al. Nephrolithiasis in Cushing’s disease: prevalence, etiopathogenesis, modification after disease cure. J Clin Endocrinol Metab 2003;88:2076-80.
Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest 1979;64:655-65.
Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J Am Soc Nephrol 1998;9:1645-52.
Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, the risk of kidney stones. JAMA 2005;293:455-62.
Ekeruo WO, Tan YH, Young MD, Dahm P, Maloney ME, Mathias BJ, et al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol 2004;172:159-63.
Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis 2006;48:905-15.
Johnson CM, Wilson DM, O’Fallon WM, Malek RS, Kurland LT. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 1979;16:624-31.
Serio A, Fraioli A. Epidemiology of nephrolithiasis. Nephron 1999;81 Suppl 1:26-30.
Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996;81:3441-7.
Aytug S, Laws ER, Vance ML. The utility of the high dose dexamethasone suppression test in confirming the diagnosis of Cushing's disease. Endocr Pract Epub ahead of print 2011.